Gain Therapeutics (GANX) Short Interest Ratio & Short Volume $2.27 -0.07 (-2.99%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.40 +0.13 (+5.51%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Gain Therapeutics Short Interest DataGain Therapeutics (GANX) has a short interest of 365,100 shares, representing 1.45% of the float (the number of shares available for trading by the public). This marks a -2.54% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.6, indicating that it would take 1.6 days of the average trading volume of 209,847 shares to cover all short positions.Current Short Interest365,100 sharesPrevious Short Interest374,600 sharesChange Vs. Previous Month-2.54%Dollar Volume Sold Short$777,663.00Short Interest Ratio1.6 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares26,520,000 sharesFloat Size25,220,000 sharesShort Percent of Float1.45%Today's Trading Volume175,227 sharesAverage Trading Volume209,847 sharesToday's Volume Vs. Average84% Short Selling Gain Therapeutics? Sign up to receive the latest short interest report for Gain Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGANX Short Interest Over TimeGANX Days to Cover Over TimeGANX Percentage of Float Shorted Over Time Gain Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/2025365,100 shares $777,663.00 -2.5%1.5%1.6 $2.13 1/15/2025374,600 shares $801,644.00 +11.8%1.5%1.5 $2.14 12/31/2024335,200 shares $724,032.00 +0.2%1.3%1.1 $2.16 12/15/2024334,700 shares $545,561.00 -42.4%1.3%1.1 $1.63 11/30/2024580,600 shares $1.08 million -19.2%2.3%1.8 $1.86 11/15/2024718,700 shares $1.33 million +9.2%2.9%1.9 $1.85 10/31/2024658,300 shares $1.65 million +15.1%2.7%1.6 $2.50 10/15/2024572,000 shares $1.37 million -12.6%2.4%1.5 $2.40 9/30/2024654,300 shares $1.16 million +12.8%2.7%1.8 $1.78 9/15/2024580,300 shares $850,139.50 +4.5%2.4%1.7 $1.47 Get the Latest News and Ratings for GANX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/2024555,400 shares $605,386.00 +195.1%2.3%1.3 $1.09 8/15/2024188,200 shares $231,486.00 +2.0%0.8%0.6 $1.23 7/31/2024184,600 shares $199,368.00 +120.3%0.8%0.6 $1.08 7/15/202483,800 shares $104,750.00 -56.6%0.5%0.3 $1.25 6/30/2024193,000 shares $247,040.00 -61.4%1.2%0.8 $1.28 6/15/2024500,300 shares $620,372.00 +521.5%3.0%2.3 $1.24 5/31/202480,500 shares $205,275.00 -20.1%0.5%0.7 $2.55 5/15/2024100,700 shares $263,834.00 -34.7%0.6%0.9 $2.62 4/30/2024154,200 shares $451,806.00 +3.1%1.0%1 $2.93 4/15/2024149,600 shares $462,264.00 +8.3%1.1%0.9 $3.09 3/31/2024138,100 shares $520,637.00 -11.9%1.0%0.9 $3.77 3/15/2024156,700 shares $672,243.00 +16.4%0.9%0.9 $4.29 2/29/2024134,600 shares $604,354.00 -2.2%0.8%0.8 $4.49 2/15/2024137,600 shares $660,480.00 +13.4%0.8%0.9 $4.80 1/31/2024121,300 shares $469,431.00 +17.2%0.7%0.8 $3.87 1/15/2024103,500 shares $361,215.00 +66.1%0.6%1.2 $3.49 12/31/202362,300 shares $203,409.50 -42.0%0.4%0.7 $3.27 12/15/2023107,400 shares $268,500.00 -25.0%0.6%1.6 $2.50 11/30/2023143,200 shares $306,448.00 -18.9%1.2%2.4 $2.14 11/15/2023176,500 shares $511,850.00 -3.2%1.7%3.8 $2.90 10/31/2023182,400 shares $521,664.00 -9.5%1.8%4.9 $2.86 10/15/2023201,600 shares $665,280.00 +6.4%2.0%4.8 $3.30 9/30/2023189,500 shares $621,560.00 +5.2%1.9%4.5 $3.28 9/15/2023180,100 shares $666,370.00 +14.1%1.8%5.5 $3.70 8/31/2023157,900 shares $522,649.00 -6.4%1.6%4.5 $3.31 8/15/2023168,600 shares $606,960.00 +61.5%1.7%4.3 $3.60 7/31/2023104,400 shares $414,468.00 +66.0%1.1%2.3 $3.97 7/15/202362,900 shares $279,276.00 -6.5%0.7%0.9 $4.44 6/30/202367,300 shares $301,504.00 +21.7%0.7%1 $4.48 6/15/202355,300 shares $269,311.00 +24.8%0.6%0.8 $4.87Watch This Robotics Demo Before March 17th (Ad)Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." Click here to watch the demo… 5/31/202344,300 shares $204,223.00 -19.6%0.5%0.5 $4.61 5/15/202355,100 shares $279,908.00 -7.9%0.6%0.7 $5.08 4/30/202359,800 shares $300,794.00 -7.1%0.7%0.8 $5.03 4/15/202364,400 shares $308,476.00 +7.3%0.7%0.9 $4.79 3/31/202360,000 shares $289,200.00 +20.2%0.7%1.1 $4.82 3/15/202349,900 shares $220,558.00 +64.1%0.6%0.9 $4.42 2/28/202330,400 shares $126,464.00 +35.7%0.3%0.7 $4.16 2/15/202322,400 shares $87,360.00 -16.7%0.3%0.5 $3.90 1/31/202326,900 shares $106,255.00 +45.4%0.3%0.7 $3.95 1/15/202318,500 shares $71,783.70 -70.5%0.2%0.5 $3.88 12/30/202262,700 shares $196,251.00 -10.7%0.6%1.9 $3.13 12/15/202270,200 shares $210,600.00 +146.3%0.7%2.3 $3.00 11/30/202228,500 shares $86,640.00 -25.4%0.3%1 $3.04 11/15/202238,200 shares $119,184.00 -21.1%0.4%1.2 $3.12 10/31/202248,400 shares $161,656.00 +6.6%0.5%1.4 $3.34 10/15/202245,400 shares $143,010.00 -30.3%0.5%1.2 $3.15 9/30/202265,100 shares $212,226.00 +50.0%0.8%1.5 $3.26 9/15/202243,400 shares $169,260.00 +80.8%0.6%1 $3.90 8/31/202224,000 shares $82,800.00 -35.0%0.3%0.5 $3.45 8/15/202236,900 shares $153,135.00 -27.8%0.5%0.7 $4.15 7/31/202251,100 shares $203,378.00 +29.4%0.7%0.7 $3.98 7/15/202239,500 shares $158,395.00 -17.9%0.5%0.5 $4.01 6/30/202248,100 shares $173,160.00 -30.9%0.6%0.3 $3.60 6/15/202269,600 shares $224,808.00 +18.2%0.9%0.4 $3.23 5/31/202258,900 shares $175,522.00 -24.6%0.8%0.4 $2.98 5/15/202278,100 shares $208,527.00 +125.1%1.0%0.5 $2.67 4/30/202234,700 shares $118,674.00 -4.9%0.5%0.2 $3.42 4/15/202236,500 shares $140,160.00 No Change0.5%0.3 $3.84 3/31/202236,500 shares $149,285.00 +18.5%0.5%0.6 $4.09 3/15/202230,800 shares $103,180.00 -17.9%0.4%0.6 $3.35 2/28/202237,500 shares $138,375.00 -42.0%0.5%0.7 $3.69 2/15/202264,700 shares $270,446.00 +100.3%0.8%1.1 $4.18 1/31/202232,300 shares $129,200.00 -8.0%0.4%0.4 $4.00 1/15/202235,100 shares $164,268.00 +30.0%0.5%0.4 $4.68 12/31/202127,000 shares $146,610.00 -25.4%0.4%0.4 $5.43 12/15/202136,200 shares $204,530.00 -14.6%0.5%0.5 $5.65 11/30/202142,400 shares $306,976.00 +74.5%0.6%0.5 $7.24 11/15/202124,300 shares $208,008.00 +35.0%0.3%0.1 $8.56 10/29/202118,000 shares $125,280.00 -23.7%0.2%0.1 $6.96 10/15/202123,600 shares $163,784.00 -5.2%0.3%0.2 $6.94 9/30/202124,900 shares $185,505.00 -63.5%0.3%0.2 $7.45 9/15/202168,200 shares $543,554.00 +170.6%0.9%0.5 $7.97 8/31/202125,200 shares $196,560.00 -42.1%0.3%0.2 $7.80 8/13/202143,500 shares $348,000.00 No Change0.6%1.6 $8.00 GANX Short Interest - Frequently Asked Questions What is Gain Therapeutics' current short interest? Short interest is the volume of Gain Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 365,100 shares of GANX short. 1.45% of Gain Therapeutics' shares are currently sold short. Learn More on Gain Therapeutics' current short interest. What is a good short interest ratio for Gain Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GANX shares currently have a short interest ratio of 2.0. Learn More on Gain Therapeutics's short interest ratio. Which institutional investors are shorting Gain Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Gain Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Gain Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.45% of Gain Therapeutics' floating shares are currently sold short. Is Gain Therapeutics' short interest increasing or decreasing? Gain Therapeutics saw a drop in short interest in January. As of January 31st, there was short interest totaling 365,100 shares, a drop of 2.5% from the previous total of 374,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Gain Therapeutics' float size? Gain Therapeutics currently has issued a total of 26,520,000 shares. Some of Gain Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Gain Therapeutics currently has a public float of 25,220,000 shares. How does Gain Therapeutics' short interest compare to its competitors? 1.45% of Gain Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Gain Therapeutics: Atyr PHARMA INC (4.66%), Immutep Limited (3.51%), Olema Pharmaceuticals, Inc. (14.68%), Korro Bio, Inc. (14.15%), Neumora Therapeutics, Inc. (18.60%), Y-mAbs Therapeutics, Inc. (10.90%), Kodiak Sciences Inc. (4.19%), Tevogen Bio Holdings Inc. (11.16%), Neurogene Inc. (11.44%), AC Immune SA (1.71%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Gain Therapeutics stock? Short selling GANX is an investing strategy that aims to generate trading profit from Gain Therapeutics as its price is falling. GANX shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Gain Therapeutics? A short squeeze for Gain Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GANX, which in turn drives the price of the stock up even further. How often is Gain Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GANX, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies ATYR Short Squeeze IMMP Short Squeeze OLMA Short Squeeze KRRO Short Squeeze NMRA Short Squeeze YMAB Short Squeeze KOD Short Squeeze TVGN Short Squeeze NGNE Short Squeeze ACIU Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GANX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GANX Stock Alerts